UK markets close in 6 hours 51 minutes
  • FTSE 100

    5,768.61
    -23.40 (-0.40%)
     
  • FTSE 250

    17,731.91
    -121.39 (-0.68%)
     
  • AIM

    973.95
    -2.43 (-0.25%)
     
  • GBP/EUR

    1.1020
    -0.0001 (-0.01%)
     
  • GBP/USD

    1.3018
    -0.0003 (-0.02%)
     
  • BTC-GBP

    10,070.16
    -2.22 (-0.02%)
     
  • CMC Crypto 200

    260.86
    -2.55 (-0.97%)
     
  • S&P 500

    3,400.97
    -64.42 (-1.86%)
     
  • DOW

    27,685.38
    -650.19 (-2.29%)
     
  • CRUDE OIL

    38.75
    +0.19 (+0.49%)
     
  • GOLD FUTURES

    1,900.90
    -4.80 (-0.25%)
     
  • NIKKEI 225

    23,485.80
    -8.54 (-0.04%)
     
  • HANG SENG

    24,787.19
    -131.59 (-0.53%)
     
  • DAX

    12,084.67
    -92.51 (-0.76%)
     
  • CAC 40

    4,741.33
    -74.79 (-1.55%)
     

Sobi shares fall 17% as Avatrombopag study fails to meet primary endpoint

·1-min read

STOCKHOLM (Reuters) - Rare disease drug maker Swedish Orphan Biovitrum (Sobi) <SOBIV.ST> said on Friday that its phase 3 study of Avatrombopag had not met its primary endpoint, sending the company's shares sharply down.

The study had been conducted to evaluate the efficacy and safety of Avatrombopag in solid tumour cancer patients withchemotherapy-induced thrombocytopenia (CIT).

Sobi added that Avatrombopag, an oral thrombopoietin receptor agonist, had increased platelet counts relative to placebo as expected.

"While we are disappointed that Avatrombopag failed to show efficacy in CIT, we are deeply grateful to the patients, investigators, and clinical site staff who contributed to the study's completion," Sobi said in a statement.

Sobi shares were down 17% at 1318 GMT.

The rival to Roche, Novo Nordisk and Shire is due to release its third-quarter report on Oct. 22.

(Reporting by Helena Soderpalm; Editing by Simon Johnson)